- Home
- ARQT vs SNDX Comparison
ARQT vs SNDX Comparison
Compare ARQT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- SNDX
- Stock Information
- Founded
- ARQT 2016
- SNDX 2005
- Country
- ARQT United States
- SNDX United States
- Employees
- ARQT 342
- SNDX N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- SNDX Health Care
- Exchange
- ARQT Nasdaq
- SNDX Nasdaq
- Market Cap
- ARQT 2.0B
- SNDX 1.2B
- IPO Year
- ARQT 2020
- SNDX 2016
- Fundamental
- Price
- ARQT $16.87
- SNDX $13.40
- Analyst Decision
- ARQT Strong Buy
- SNDX Strong Buy
- Analyst Count
- ARQT 6
- SNDX 10
- Target Price
- ARQT $18.80
- SNDX $36.20
- AVG Volume (30 Days)
- ARQT 2.7M
- SNDX 1.9M
- Earning Date
- ARQT 05-13-2025
- SNDX 03-03-2025
- Dividend Yield
- ARQT N/A
- SNDX N/A
- EPS Growth
- ARQT N/A
- SNDX N/A
- EPS
- ARQT N/A
- SNDX N/A
- Revenue
- ARQT $196,542,000.00
- SNDX $23,680,000.00
- Revenue This Year
- ARQT $56.60
- SNDX $274.86
- Revenue Next Year
- ARQT $43.62
- SNDX $130.47
- P/E Ratio
- ARQT N/A
- SNDX N/A
- Revenue Growth
- ARQT 229.74
- SNDX N/A
- 52 Week Low
- ARQT $6.99
- SNDX $12.06
- 52 Week High
- ARQT $17.75
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- ARQT 67.97
- SNDX 45.94
- Support Level
- ARQT $16.27
- SNDX $13.39
- Resistance Level
- ARQT $17.50
- SNDX $14.29
- Average True Range (ATR)
- ARQT 1.09
- SNDX 0.68
- MACD
- ARQT 0.25
- SNDX 0.04
- Stochastic Oscillator
- ARQT 94.23
- SNDX 54.66
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.